Systemic Lupus Erythematosus
Lupus erythematosus is an autoimmune disease that can manifest itself in several different ways including: discoid lupus erythematosus (DLE), systemic lupus erythematosus (SLE), drug-induced lupus, late-state lupus, and antiphopholipid antibody syndrome. Systemic lupus erythematosus (SLE) is a chronic, rheumatic, inflammatory disease that can affect a person’s skin, joints, kidneys, lungs, heart, nervous system, blood, and mucous membranes. It does not affect all patients in the same way, so patients experience variable organ involvement after being diagnosed with SLE.  
Occurs in 15-24/100,000 people throughout the world 
Large variation depending on country and location--high prevalence in Sweden. 14.6/100,000 in NY vs 78.5/100,000 in WI
Most likely to occur in women of child-bearing age
More common in those of African American, Hispanic, Asian, and Native American decent than in Caucasians 
9 times more likely in women compared to men 
Most people are diagnosed with the disease between the ages of 15 and 40 
Rarely diagnosed in the elderly 
Occurs in 10-20/100,000 children (depends on the population)
About 15% of people diagnosed with SLE are younger than 18 years old, and when a person is diagnosed at an early age, the disease progresses more quickly and severely than if diagnosed after the age of 18. 
More prevalent in those who have a family history of SLE than it is in the general population 
The exact cause of SLE is unknown but research suggests that genetics may be a contributing factor, but not the only factor.  Hormonal and environmental factors have also been identified as playing a role in the onset of the condition.   The consensus however is that autoimmunity is thought to be the primary causative factor of SLE. The following are some of the factors that can predispose a person to SLE: 
Heredity- There is a high prevalence of SLE in first-degree relatives. The immune abnormalities associated with SLE can be triggered by both internal and external factors.
Stress- It has been determined that stress can provoke changes in the neuroendocrine system causing changes in the function of immune system cells.
Bacterial or viral infection- The Epstein-Barr virus has been found to be a risk factor for the development of SLE.
Sunlight or UV exposure
Pregnancy- The evidence about whether or not pregnancy can cause exacerbations of SLE is very inconclusive because some studies state that pregnancy does affect the course of SLE, while others state that it has no affect on the course of the disease.
Abnormal levels of estrogen
Certain drugs- Drugs such as hydralazin, anticonvulsants, penicillin, sulfa drugs, and oral contraceptives can change the cellular responsiveness and immunogenicity of self-antigens and therefore make a person more susceptible to SLE. 
Phthalates (a chemical used to soften and increase the flexibility of plastics)
Although the cause of this condition is unknown the process is fully understood "the body creates antibodies against its own cells." These antibodies can be formed against many different tissues and components of the body including red blood cells, neutrophils, platelets, lymphocytes. This accounts for the fact that SLE can affect almost any area of a person's body. 
SLE can affect many organs of the body, but it rarely affects them all. The following list includes common signs and symptoms of SLE in order of the most to least prevalent. All of the below symptoms might not be present at the initial diagnosis of SLE, but as the disease progresses more of a person’s organ systems become involved.  The most common symptoms associated with SLE are:
Constitutional symptoms (fever, malaise, fatigue, weight loss): most commonly fatigue and a low-grade fever
Achy joints (arthralgia)
Pulmonary involvement (symptoms include: chest pain, difficulty breathing, and cough)
Sensitivity to the sun or light (photosensitivity)
CNS involvement (seizures, headaches, peripheral neuropathy, cranial neuropathy, cerebrovascular accidents, organic brain syndrome, psychosis)
Mouth, nose, or vaginal ulcers” 
The most common signs and symptoms of SLE in children and adolescents are: "fever, fatigue, weight loss, arthritis, rash, and renal disease." 
There are many visceral systems can be affected from SLE, but the extent of the body's involvement differs from person to person. Some people diagnosed with SLE have only few visceral systems involved, while others have numerous systems that have been affected by the disease.
Arthritis- typically affects hand, wrists, and knees
Glomerulonephritis -inflammatory disease of the kidneys
Some types of cancers (especially non-Hodgkin's lymphoma and lung cancer)   
Avascular Necrosis 
Because of the many different symptoms and manifestations of SLE early detection can often be difficult. According to the American Rheumatism Association, a patient must exhibit at least 4 of the following criteria concurrently or successively to be diagnosed with systemic lupus erythematosus.
Abnormal titer of antinuclear antibodies (ANAs)
Butterfly (malar) rash
Hemolytic anemia, leukopenia, lymphopenia, thrombocytopenia
Neurologic disorder: seizures or psychosis
Non-erosive arthritis of two or more peripheral joints characterized by tenderness, swelling, or effusion
Oral or nasopharyngeal ulcerations
Pleuritis or pericarditis
Positive lupus erythematosus cell preparations, anti DNA, or anti-splice sosomal test or chronic false-positive serologic test for syphilis
Renal disorder: profuse proteinuria (>0.5 grams/day) or excessive cellular casts in urine." 
Although laboratory tests along cannot diagnose SLE the following tests may show abnormal results if SLE is suspected:
Complete Blood Count: This blood test reveals a patient's total number of red blood cells, white blood cells, platelets, and hemoglobin. Low white blood cell or platelet counts can be indicative of SLE, whereas low red blood cell counts can be indicate of anemia which commonly occurs in conjunction with SLE.
Erythrocyte Sedimentation Rate: An elevated erythrocyte sedimentation rate can reveal a systemic problem. This test is not specific to SLE, but a postitive test could reveal that the patient could potentially have SLE.
Kidney and Liver Tests: These tests are completed to determine if a patient's kidneys and liver are functioning properly since SLE can affect these systemic organs.
Urinalysis: This test is performed to determine if there are proteins or red blood cells present in a patient's urine. If so, this could indicate that the kidneys are damaged, potentially from SLE.
ANA test: A positive test reveals that a patient could potentially have SLE, but other infections and diseases can cause this test to be positive as well. If positive, further testing is necessary to determine if the positive results occurred due to SLE.
Chest X-ray: This test is performed to determine if there is inflammation present in the patient's lungs or excessive fluid surrounding his/her heart.
Syphilis Test: A false-positive syphilis test can reveal that a patient has anti-phospholipids present, and this false-positive test result is indicative that the patient could have SLE. 
The medical management for SLE is primarily drug therapy and is based upon the patients symptoms and systemic involvement. The most widely used medications are:
Analgesics  : These medications are used to control the pain associated with arthralgia, arthritis, and ulcers that are caused by SLE. 
Non-Steroidal Anti-inflammatory Drugs (NSAIDS): These medications help to decrease tissue inflammation, and therefore decrease the patient’s joint and muscle pain.
Anti-malarials: These medications are used to treat a patient's arthritic, musculocutaneous, and renal symptoms associated with SLE.
- Cyclophosphamide (Cytoxan)  
In addition to drug therapy, prevention is also very important when dealing with SLE. For patients with photosensitivities, flare-ups can be reduced if patients are cautious about the amount of sunlight or UV light that they are exposed to. Patients with SLE are also encouraged to lead a healthy lifestyle that includes: smoking cessation, controlling alcohol consumption, weight management, and regular exercise.   Patients with SLE are also encouraged to participate in support groups, ensure they are taking the correct dosages and amounts of medications, and ensure they visit medical professionals regularly.  There are also other therapies that claim to have a positive effect on symptoms, such as:
Biological Therapy 
Physical Therapy Management
Exercise is beneficial for patients with SLE because it decreases their muscle weakness while simultaneously increases their muscle endurance. Physical therapists can play an important role for patients with SLE during and between exacerbations. The patient's need for physical therapy will vary greatly depending on the systems involved.
Education: It is essential for patients with skin lesions to have appropriate education on the best way to care for their skin and to ensure they do not experience additional skin breakdown.
Aerobic Exercise: One of the most common impairments that patients with SLE experience is generalized fatigue that can limit their activities throughout the day.  In a study by Tench et al., it was determined that graded aerobic exercise programs are more successful than relaxation techniques in decreasing the fatigue levels of patients with SLE. Aerobic activity caused many of the participants with SLE to feel "much better" or "very much better" at the conclusion of the study. The aerobic exercise program consisted of 30-50 minutes of aerobic activity (walking/swimming/cycling) with a heart rate corresponding to 60% of the patient's peak oxygen consumption.  Another study, completed by Ramsey- Goldman et al., concluded that both aerobic exercise and range of motion/muscle strengthening exercises can increase the energy level, cardiovascular fitness, functional status, and muscle strength in patients with SLE. In this study, the patients completed aerobic exercise for 20-30 minutes at 70-80% of their maximum heart rate. The patients who completed range of motion and muscle strengthening activities met 3 times a week for 50 minutes sessions. 
Energy Conservation: Physical therapists can educate patients on appropriate energy conservation techniques and the best ways to protect joints that are susceptible to damage.
Additionally, physical therapists and patients with SLE should be aware of signs and symptoms that suggest a progression of SLE including those associated with avascular necrosis, kidney involvement, and neurological involvement. 
Due to the vast differences in systems and parts of the body involved SLE can often be mistaken for another condition and vice-versa. ANA Profiling is a common procedure to confirm or negate a diagnosis of SLE.
Antinuclear antibodies (ANA) are a group of autoantibodies produced by a person's immune system when the body is unable to distinguish between "self" and "nonself." The ANA Profile Test detects these autoantibodies in the blood. ANA cause a reaction with the body's own healthy cells causing signs and symptoms associated with SLE and other autoimune conditions. (SLE) are almost always positive for ANA, but the test alone is not enough to confirm diagnosis of SLE, other SLE symptoms must be present. If the ANA profile test is negative a diagnosis of SLE is unlikely   The test has a sensitivity of 93% and a specificity of 57%  . Other conditions that have similar symptoms to SLE are:
↑ 6.0 6.1 6.2 "Handout on Health: Systemic Lupus Erythematosus" . www.niams.nih.gov. June 2016.(Accessed 28 April 2019).
↑ 7.0 7.1 Lisnevskaia, L., Murphy, G., & Isenberg, D. (2014). Systemic lupus erythematosus. The Lancet, 384(9957), 1878–1888.
↑ Lupus Foundation of America. How lupus affects the body page. Website updated: 2010. Website accessed: February 17, 2010.
↑ Becker-Merok A, Nossent JC. Prevalence, predictors, and outcomes of vascular damamge in systemic lupus erythematosus. Lupus; 18: 508-515. 2009.
↑ 10.0 10.1 10.2 10.3 Bertsias G, Gordon C, Boumpas DT. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future- the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus; 17: 437-442. 2008.
↑ Wingard R. Increased risk of anemia in dialysis patients with comorbid diseases. Nephrology Nursing Journal; 31 (2): 211-214. 2004.
↑ 12.0 12.1 Medical Foundation for Medical Education and Research. Mayo Clinic: Lupus Page. www.mayoclinic.com. Updated October 20, 2009. Accessed February 17, 2010.
↑ Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus.Arthritis & Rheumatism 2005;52(5):1481–90.
↑ Solsky M, Wallace D. New therapies in systemic lupus erythematosus. Best Practice & Res Clin Rheum: 2002; 16; 293-312
↑ Tench CM, McCarthy J, McCurdie I, White PD, D'Cruz DP. Fatigue in systemic lupus erythematosus: a randomized control trial of exercise. Rheumatology; 42: 1050-1054. 2003. (Level of evidence 1B)
↑ Ramsey-Goldman GR, Schilling EM, Dunlop D, Langman C, Greenland P, Thomas RJ, Chang RW. A pilot study on the effects of exercise in patients with systemic lupus erythematosus. Arthritis Care and Research; 13(5): 262-269. 2000. (Level of evidence 2B)
↑ Hochberg MC. Updating the American College of Rehumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism 1997; 40: 1725-1734
↑ George R, Kurian S, jacob M, Thomas K. Diagnostic evaluation of the lupus band test in discoid and systemic lupus erythematosus. Int J Dermatol. 1995 34: 170-173
↑ Mehta V, Sarda A, Balachandran C. Lupus band test. Indian J Dermatol Venereol Leprol [serial online] 2010 [cited 2012 Mar 6];76:298-300. Available from: http://www.ijdvl.com/text.asp?2010/76/3/298/62983
↑ Solomon DH, Kavanaugh AJ, Schur PH, American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence‐based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Care & Research. 2002 Aug 15;47(4):434-44.
↑ Bhiglee AI, Bill PL. Case Report: Multiple sclerosis and SLE revisited. Medical Journal of Islamic Academy of Sciences; 12 (3): 79-84. 1999.